Clinical Trial Update: A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 [Phase 1, Phase 2]

View source ↗

Summary

INT230-6 was evaluated in a Phase 1/2 safety study using intratumoral dosing in breast cancer and head and neck cancer. Results were posted on 2024-08-13.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Head and Neck Cancer

Drugs mentioned

• INT230-6

Snippet

Sponsor: Intensity Therapeutics, Inc. | Conditions: Breast Cancer, Head and Neck Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2024-08-13